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Abstract
Background: L-2-hydroxyglutaric aciduria is a rare autosomal recessive encephalopathy caused by mutations in the
L-2-hydroxyglutarate dehydrogenase gene. We describe some novel clinical and molecular characteristics found in a
boy with L-2-hydroxyglutaric aciduria.
Case presentation: We report an 8-year-old Chinese boy, who had characteristic developmental delay, ataxia and
acrocephaly as the main symptoms. He also complained of paroxysmal headache and palpitation. Brain image
revealed a symmetrical, extensive subcortical white matter lesion. Urine test for organic acids showed a significantly
increased level of 2-hydroxyglutaric acid (106.74 mmol/mol cre, normal range 0.6 ~ 5.9 mmol/mol cre), leading to
the diagnosis of L-2-hydroxyglutaric aciduria. Genetic testing uncovered two heterozygous missense mutations in
L-2-hydroxyglutarate dehydrogenase gene: c.169G > A in exon 2 and c.542G > T in exon 5, not hitherto been described.
Conclusion: Novel gene mutation and associated clinical symptoms can contribute for the understanding and
identification of this rare disease. Possible genotype-phenotype correlation waits for further study.
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Background
L-2-hydroxyglutaric aciduria is a rare autosomal reces-
sive encephalopathy caused by mutations in the L-2-
hydroxyglutarate dehydrogenase gene. Several clinical
descriptions have appeared on L-2-hydroxyglutaric acid-
uria (L-2-HGA) since the index case reported in 1980
[1]. With insidious onset in childhood, the disease pro-
gresses slowly. The cardinal clinical signs include de-
velopmental delay, epilepsy and cerebellar ataxia, with
half of the patients showing macrocephaly [2]. A mito-
chondrial enzyme, L-2-hydroxyglutarate dehydrogen-
ase, catalyses the oxidation of L-2-hydroxyglutaric acid
to alpha-ketoglutarate. Its functional defect leads to ac-
cumulation of L-2-hydroxyglutaric acid. Numerous
mutations in L-2-hydroxyglutarate dehydrogenase gene
have now been reported in L-2-HGA patients world-
wide, registered in the Leiden Open Variation Database
[3]. Currently, 92 unique variants have been described
in 241 individuals who are homozygous or compound
heterozygous for these alleles, and the majority of
them are missense mutations. Here we describe some
novel clinical and molecular characteristics found in a
boy with L-2-hydroxyglutaric aciduria.
Case presentation
An 8-year-old boy presented to our hospital for develop-
mental delay and ataxia. He was born by cesarean sec-
tion after fetal distress at 41 weeks gestation, with
macrocephaly. He could not walk or speak a single word
like ‘mom’ until 26 months of age. At approximately
4 years of age, his parents became concerned that he
walked unstably, falling easily. He developed slight weak-
ness and fatigue. In addition, he had paroxysmal head-
ache and palpitation, aggravating muscle weakness. He
had no convulsion, loss of consciousness, nausea, vomit-
ing or blurred vision. During an episode of palpitation,
lasting 2-3 minutes, the heart rate could reach 130-140
beats per minute, precipitating weakness, which resolved
spontaneously in half an hour. His symptoms worsened
continually. On entering a primary school at 8-years of
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age, he had difficulty keeping up with his peers. Family
history reviewed no developmental delay, motor abnor-
malities or consanguinity. He had healthy parents and
an older sister.
On examination, he was a little irritable. He showed
normal orientation and comprehension for age, but
could not do simple calculation. He had neither muscu-
lar hypertrophy nor atrophy, showing muscle strength of
grade 5 minus (MRC), and normal muscle tone. He had
symmetrical hyperreflexia and bilateral Babinski’s signs.
He could not do well in tandem gait, or finger-to-nose
and heel-knee-tibia test.
Brain MRI showed symmetrical, extensive subcortical
hyperintense white matter lesion on T2-weighted se-
quences and diffusion-weighted imaging (DWI), involv-
ing bilateral dentate nucleus, internal capsule, external
capsule and corona radiate (Fig. 1). Urinary organic
acid screening with gas chromatography mass spec-
trometry (GC-MS) revealed significantly increased 2-
hydroxyglutaric acid (106.74 mmol/mol cre, normal
range 0.6 ~ 5.9 mmol/mol cre) (Fig. 2), 3-hydroxyglutaric acid
(537.83 mmol/mol cre, nomal range 0) and 2- hexane acid
(113.02 mmol/mol cre, normal range 0~ 16.4 mmol/mol
cre), leading to the probable diagnosis of L-2-
hydroxyglutaric aciduria.
The patient received riboflavin 5 mg three times per
day and oral L-carnitine 1 g per day, which stabilized the
symptoms for one year. When he stopped the medica-
tion, the frequency of headache and palpitation in-
creased. On his return 3 years later, brain MRI showed
no obvious change. Genetic screening, conducted on this
admission, identified two heterozygous mutations in the
L-2-hydroxyglutarate dehydrogenase gene: G > T trans-
version (c.542G > T; p.G181V) in exon 5, and G > A
transversion (c.169G > A; p.G57R) in exon 2 (Fig. 3).
Familial gene analysis showed his father had the hetero-
zygous mutation c.542G > T and his mother, the other
heterozygous mutation c.169G > A.
Conclusions
This patient had several characteristic symptoms such as
developmental delay, ataxia, pyramidal impairment and
macrocephaly, in combination with an elevated 2-
hydroxyglutaric acid in urine. In gene test, he had a com-
pound heterozygous missense mutation. The c.169G >A
in exon 2 was firstly reported to be pathogenic in 2005
[4]. The other one c.542G > T in exon 5 was a novel muta-
tion, which had not been reported before. The mutation
located in conserved region. We used three tools includ-
ing SIFT, PlyPhen and Mutationtaster to predict the
Fig. 1 The patient’s brain magnetic resonance image (MRI). Axial T2-weighted sequence of the brain MRI showed symmetrical subcortical white
matter hyperintense involving bilateral dentate nucleus, internal capsule, external capsule, and corona radiate
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Fig. 2 The patient’s urinary organic acid screening with GC-MS, showing increased 2-hydroxyglutaric acid concentrations
Fig. 3 The patient’s L-2HGDH gene mutations. The patient’s L-2HGDH gene test showed two heterozygous mutations: c.542G > T in exon5 and
c.169G > A in exon2
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possible impact of the amnio acid substitution on the
structure and function of the protein L-2-hydroxyglutarate
dehydrogenase. The test results indicated it was ‘dele-
terious (0 score), probably damaging (1 score) and dis-
ease causing’ respectively. This suggests that the
mutation is probably to be pathogenic. Further func-
tional test is in need.
Despite the general believe that the disease has highly
homogeneous phenotype, our patient showed some
novel symptoms. He had attacks of paroxysmal headache
and palpitation, which worsened weakness. The accumu-
lation of L-2-hydroxyglutaric acid causes leukoencepha-
lopathy, with possible involvement of the autonomic
nervous system, which may contribute to paroxysmal
palpitation. Alternatively, paroxysmal palpitation and
weakness may result from increased L-2-hydroxyglutaric
acid accumulated in peripheral organs such as heart and
muscle, in addition to the central nervous system as pre-
vious described [5] Possible genotype-phenotype correl-
ation waits further investigation.
Supplementation with FAD and its precursor riboflavin
may foster the residual enzymatic activity of L-2-
hydroxyglutarate dehydrogenase with increased oxidation
of L-2-hydroxyglutaric acid, thereby reducing its toxicity
[6]. Previous studies showed a success with riboflavin
(100 mg/day) and FAD (30 mg/day) therapy in some cases
[7, 8], but not in others. In our patient, symptoms stabi-
lized during the one year treatment, with its recurrence
after discontinuation of therapy.
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